EntyvioVedolizumab Long Term Study
Research payments
$1,248,246
Through program year 2019, $1,248,246 in research payments was reported against EntyvioVedolizumab Long Term Study, across 168 payments, paid by Takeda Pharmaceuticals U.S.A., Inc..
- Paid by
- Takeda Pharmaceuticals U.S.A., Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $1,248,246 | 168 |
Breakdown
Usually the institution or organisation running the study, not a person.
Only reported on some payments, and a payment can report more than one category, so these amounts overlap.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Razvan Arsenescu Morristown, NJ Named on 7 payments
- Robin Dalal Nashville, TN Named on 6 payments
- Gauree Konijeti La Jolla, CA Named on 5 payments
- Keith Sultan Manhasset, NY Named on 5 payments
- Robert Isfort Cincinnati, OH Named on 5 payments
- James Marion New York, NY Named on 4 payments
- John Gancayco Jbsa Ft Sam Houston, TX Named on 4 payments
- Edward Loftus Rochester, MN Named on 4 payments
- Tuba Esfandyari Kansas City, KS Named on 4 payments
- Kim Isaacs Chapel Hill, NC Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.